Quidel Corporation 

(Public, NASDAQ:QDEL)   Watch this stock   
Find more results for QDEL
Oct 19, 2009
Q3 2009 Earnings Conference Call - Webcast
Oct 16, 2009
Q3 2009 Earnings Release
Oct 6, 2009
William Blair & Company Emerging Growth Stock Conference
Sep 21, 2009
UBS Global Life Sciences Conference
Sep 17, 2009
CL King and Associates Best Ideas Conference
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin 26.61% 14.71%
Operating margin 43.20% 22.34%
EBITD margin - 29.11%
Return on average assets 44.62% 13.63%
Return on average equity 54.83% 16.61%
Employees 322 -

Address

10165 McKellar Court
San Diego, CA 92121
United States - Map
+1-858-5521100 (Phone)
+1-858-4534338 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

Quidel Corporation discussed on blogs

Ranking 1300+ Small Cap Stocks by Cash Flow Per Share - NASD100 ... - Investor's Resources - NASD100.com - Daily Stock Rankings - 6 hours ago

Quidel Corporation discussions

  View all discussions »

Description

Quidel Corporation is engaged in the development, manufacturing and marketing of rapid diagnostic solutions for decentralized applications, including professional point-of-care (POC) in infectious diseases, reproductive and women’s health. The Company focuses on POC testing solutions specifically developed for the physician office lab (POL) and acute care markets globally. It sells its products to professionals for use in physician offices, hospitals, clinical laboratories and wellness screening centers. Its POC testing solutions are designed to provide specialized results that meet two value criteria that the Company has branded as Quidel Value Build (QVB). The Company provides rapid POC and other diagnostic tests under brand names, including QuickVue, QuickVue+, QuickVue Advance, Metra, Quidel and MicroVue. The Company markets its products in the United States through a network of national and regional distributors, supported by a direct sales force.

Officers and directors

Mark A. Pulido
Chairman of the Board
Age: 56
Bio & Compensation - Reuters
Douglas C. Bryant
President, Chief Executive Officer, Director
Age: 51
Bio & Compensation - Reuters
John M. Radak
Chief Financial Officer
Age: 48
Bio & Compensation - Reuters
Robert Joseph Bujarski J.D
Senior Vice President, General Counsel, Corporate Secretary
Age: 40
Bio & Compensation - Reuters
John D. Tamerius Ph.D.
Senior Vice President - Clinical, Regulatory Affairs
Age: 63
Bio & Compensation - Reuters
Richard C. Tarbox III
Senior Vice President, Corporate Development Officer
Age: 57
Bio & Compensation - Reuters
Scot M. McLeod
Senior Vice President - Operations
Age: 44
Bio & Compensation - Reuters
Tim Stenzel M.D., Ph.D.
Chief Scientific Officer
Bio & Compensation - Reuters
Mary Lake Polan M.D., Ph.D.
Director
Age: 65
Bio & Compensation - Reuters
Thomas D. Brown
Director
Age: 60
Bio & Compensation - Reuters